NCM Boston | Oxford Nanopore Technologies
NCM Boston
A
)
Andreas CzechBioNTech, Germany
)
Alex KneubehlBaylor College of Medicine, USA
)
Anne-Sophie LebreCHU Reims, France
)
Ailsa MacCalmanUniversity of Exeter, UK
)
Anastasia McKinlayIndiana University & HHMI, USA
)
Amit MathurSanofi, USA
)
Ana PeresThe University of North Carolina at Chapel Hill, USA
)
Aaron VinyColumbia University Irving Medical Center, USA
)
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
B
)
Bronya BoydonMachine Learning Bioinformatician, Oxford Nanopore Technologies
)
Bradley HallAsuragen, USA
)
Bryan LelandBioinformatics Manager, Commercial Applications, Oxford Nanopore Technologies
)
Benjamin C. ReinerUniversity of Pennsylvania, USA
)
Brynja SigurpálsdóttirdeCODE genetics, Iceland
C
)
Cory BernhardsDEVCOM Chemical Biological Center, USA
)
Chris BrownVP Strategic Programmes, Oxford Nanopore Technologies
)
Colette CôtéPathoQuest, USA
)
Christian GallardoSeattle Children's Research Institute, USA
)
Carol GreiderUniversity of California, Santa Cruz, USA
)
Chun-Chieh LinDartmouth Health, USA
)
Chad PollardWasatch BioLabs, USA
)
Charles A. SwoffordMIT Center for Biomedical Innovation, USA
)
Carly TyerApplications Scientist, Oxford Nanopore Technologies
)
Carika WeldonCariGenetics, Bermuda
D
)
Daniel K. FabianLonza, UK
)
Dan FordhamDirector, Strategic Product Management EMEA, Oxford Nanopore Technologies
)
Daniel KimUniversity of California, Santa Cruz, USA
)
Dmitrijs RotsErasmus MC, Netherlands
)
David VanHouteRegeneron Pharmaceuticals, USA
)
David YarmoshATCC, USA
)
)
G
)
Gabriela PozoUniversity of San Francisco de Quito, Ecuador
)
Gordon SangheraCEO, Oxford Nanopore Technologies
)
Gaston VondenhoffLonza, The Netherlands
H
)
Heather CarletonCenters for Disease Control & Prevention, USA
)
Helen GunterThe BASE Facility, The University of Queensland, Australia
J
)
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
)
Justin BeckerDana-Farber Cancer Institute & Massachusetts General Hospital, USA
)
Jade BartoloAssociate Director, Automation, Oxford Nanopore Technologies
)
Jack ColicchioSound Agriculture, USA
)
Julie CollensVP, Commercial Operations AMR, Oxford Nanopore Technologies
)
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
)
J. (Gus) GustafsonUniversity of Washington, USA
)
Julie HaendigesU.S. Food and Drug Administration, USA
K
)
Karine ChoquetUniversity of Sherbrooke, Canada
)
Keith ConnollyModalis Therapeutics, USA
)
Kamil KhanipovThe University of Texas Medical Branch, USA
)
Katherine LawrenceMachine Learning and Bioinformatics Manager, Oxford Nanopore Technologies
L
)
Lucia DaxingerLeiden University Medical Center, Netherlands
)
Lantana GrubVanderbilt University, USA
)
Lakmal JayasingheSenior VP, R&D Biologics, Oxford Nanopore Technologies
)
Laura KamenetzkyCONICET, Argentina
)
Logan MulroneyEMBL-EBI, UK & IIT, Italy
M
)
Matthew BainbridgeRady Children's Institute for Genomic Medicine, USA
)
Michael DeanNational Cancer Institute, USA
)
Mathilde FilserCurie Institute, France
)
Megan L. NoonanWashington University School of Medicine in St. Louis, USA
)
Matt ParkerDirector, Clinical Bioinformatics Software, Oxford Nanopore Technologies
)
Mile SikicGenome Institute of Singapore, A*STAR, Singapore
)
Mike VellaSenior Director, Machine Learning, Oxford Nanopore Technologies
)
)
P
)
Philipp ReschenederSenior Director, Applications Bioinformatics, Oxford Nanopore Technologies
)
Paula SaffieClinica Santa María, Chile
)
R
)
Ranjith AnandeGenesis, USA
)
Rachel O’NeillUniversity of Connecticut, USA
)
Rachel RubinsteinTechnical Product Manager, Software, Oxford Nanopore Technologies
)
Rosemary Sinclair DokosSenior VP, Product and Programme Management, Oxford Nanopore Technologies
)
Radhakrishna TirumalaiMerck & Co., USA
)
Rhydian WindsorResearch Scientist, Machine Learning, Oxford Nanopore Technologies
S
)
Stacy L. SpringsMIT Center for Biomedical Innovation, USA
)
Stephanie AbernathyVice President, Sales, Americas, Oxford Nanopore Technologies
)
Stephanie ChrysanthouMemorial Sloan Kettering Cancer Center, USA
)
Scott HickeyDirector, Commercial Applications, Oxford Nanopore Technologies
)
Shilpa KobrenHarvard Medical School, USA
)
Serge MonpoehoRegeneron Pharmaceuticals, USA
)
Svetlana MadjunkovaCReATe Fertility Centre, Canada
)
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
)
Samuel ShelburneThe University of Texas MD Anderson Cancer Center, USA
)
Sebastian B. TeitzveryTeitz Consulting, Germany
T
)
Thomas GarciaBaylor College of Medicine, USA
)
Tasos GogakosArena BioWorks & Massachusetts General Hospital, USA
)
Tim WalkerApplied Industrial Support Specialist, Oxford Nanopore Technologies
)
)
)
Oxford Nanopore Technologies
Matt Parker
)
- Job title
- Institution
- Director, Clinical Bioinformatics Software, Oxford Nanopore Technologies
- Biography
Dr. Matt Parker is Director, Clinical Bioinformatics Software at Oxford Nanopore Technologies and sits in the Customer Workflows (EPI2ME) team. The Customer Workflows team produce bioinformatics analysis workflows and platforms (EPI2ME) for the analysis of Oxford Nanopore sequencing data. As a health care and professionals council registered clinical bioinformatician, Matt is interested in the potential of Oxford Nanopore sequencing to improve human health through better genomic diagnostics. Matt and his team are focused on developing medical device grade analysis workflows across infectious diseases, rare disease, and cancer that can be deployed on Oxford Nanopore devices and in the cloud to take Oxford Nanopore sequencing reads and derive meaningful clinical interpretations.